JPRN-UMIN000000608已完成未知
Phase III randomized comparative study of combination therapy with CDDP and TS-1 vs. combination therapy with CDDP and Docetaxel in stage IIIB/IV non-small cell lung cancer - Phase III randomized comparative study of combination therapy with CDDP and TS-1 vs. combination therapy with CDDP and Docetaxel in stage IIIB/IV non-small cell lung cancer (CATS Trial) (CATS Trial)
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 600
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.With adjuvant chemotherapy 2.History of serious drug allergy 3.Active concomitant malignancy 4.Serious complications 5.Proven or suspected infections diseases 6.Symptomatic brain metastasis 7.Watery diarrhea or Chronic constipation 8.Pleural effusion,peritoneal fluid,and pericardial fluid 9.Concomitant therapy with another anticancer drug or flucytocine 10.Pregnancy,breast feeding or wish of future bearing 11.Mental disease or psychotic manifestation 12.It participated in the development clinical trial of and others within 1 month 13.Other conditions not suitable for this study
研究者
相似试验
已完成
不适用
PHASE III RANDOMIZED STUDY COMPARING THE COMBINATION OF GEMCITABIN WITH CARBOPLATINE VERSUS THE CARBOPLATINE MONOTHERAPY, IN PATIENTS WITH ADVANCED EPITHELIAL OVARY CANCER WHOSE RESULTS WITH FIRST-LINE THERAPY WITH PLATINUM WERE NOT SATISFACTORY-C56 Malignant neoplasm of ovaryMalignant neoplasm of ovaryC56PER-056-01ELI LILLY INTERAMERICA INC.,
招募中
3 期
PHOENIX-GC2 trialJPRN-jRCT2031200087Ishigami Hironori262
已完成
3 期
A phase III clinical study to compare the combination therapy of eribulin mesylate + trastuzumab + pertuzumab with paclitaxel or Docetaxel + trastuzumab + pertuzumabJPRN-UMIN000027938Japan Breast Cancer Research Group446
进行中（未招募）
3 期
JBCRG-M06(EMERALD)HER2-positive progressive-recurrent breast cancerJPRN-jRCTs021180027Yamashita Toshinari480
进行中（未招募）
1 期
Comparing two treatment regimen for sinuses tumors and salivary glands: radiotherapy versus chemoradiotherapyEUCTR2016-001816-39-BEGORTEC342